Inclusion Criteria:

1. Documented cancer of the pancreas who have failed (or are not candidates for)
standard therapy

2. ECOG Performance Status of 0 to 1

3. Adequate organ function as defined by study-specified laboratory tests

4. Must use acceptable form of birth control through the study and for 28 days after
final dose of study drug

5. Signed informed consent form

6. Willing and able to comply with study procedures

Exclusion Criteria:

1. Currently have or have history of certain study-specified heart, liver, kidney, lung,
neurological, immune or other medical conditions

2. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the
National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events
(CTCAE), version 3.0

3. Systemically active steroids

4. Another investigational product within 28 days prior to receiving study drug

5. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring
within 28 days prior to receiving study drug

6. Infection with HIV, hepatitis B or C at screening

7. Pregnant or lactating

8. Conditions, including alcohol or drug dependence, or intercurrent illness that would
affect the patient's ability to comply with study visits and procedures